<DOC>
	<DOCNO>NCT00889863</DOCNO>
	<brief_summary>This two-part study assess sustain efficacy canakinumab double-blind Part II ability taper steroid open label Part I .</brief_summary>
	<brief_title>Flare Prevention Study Canakinumab Patients With Active Systemic Juvenile Idiopathic Arthritis ( SJIA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Confirmed diagnosis systemic juvenile idiopathic arthritis per International League Against Rheumatism ( ILAR ) definition must occur least 2 month prior enrollment onset disease &lt; 16 year age . Arthritis one joint precede fever least 2 week duration document daily least 3 day accompany symptom Active disease time enrollment define follow : At least 2 joint active arthritis ( use American College rheumatology ) ACR definition active joint ) Documented spiking , intermittent fever ( body temperature &gt; 38oC ) least 1 day screen period within 1 week first study drug dose Creactive protein &gt; 30 mg/L ( normal range &lt; 10 mg/L ) No concomitant use second line agent diseasemodifying and/ immunosuppressive drug allow exception : Stable dose methotrexate least 8 week prior screen visit , and/or folic/folinic acid per standard medical practice Stable dose one nonsteroidal antiinflammatory drug least 2 week prior screen visit Stable dose steroid treatment &lt; = 1.0 mg/kg/day 12 dos per day oral prednisone equivalent Exclusion criterion : Diagnosis active macrophageactivation syndrome ( MAS ) within last 6 month Risk factor tuberculosis Patients active recurrent bacterial , fungal viral infection time enrollment , include patient evidence HIV infection , Hepatitis B Hepatitis C infection Other protocol inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Flare</keyword>
	<keyword>arthritis</keyword>
	<keyword>IL-1beta antagonist</keyword>
	<keyword>systemic juvenile idiopathic arthritis</keyword>
	<keyword>Juvenile rheumatoid</keyword>
</DOC>